All posts by medical

Program to focus on lung anatomy and basic medication – Newton Daily News

The Goodwill Career Connection Center, 600 N. Second Ave. W., Room 241 in Newton, is hosting a Lung Anatomy and Basic Medication event from 2 to 3 p.m. April 20.

The featured speaker will be Dr. Holly Melahoures. The program is presented by the CareMore Clinic, 1530 E. Euclid Ave. in Des Moines. Light refreshments and snacks will be provided.

Smoking is the leading cause of preventable death in the U.S., causing over 480,000 deaths per year. Secondhand smoke is a serious health hazard for people of all ages, causing more than 41,000 deaths each year. In 1987, lung cancer surpassed breast cancer as the leading cause of cancer deaths among women in the U.S. Among African-American high school students, cigars were the most commonly used tobacco product; among Hispanic high school students it was electronic cigarettes.

For more information about the American Lung Association of Iowa Better Breathers Club call 515-989-6001 or visit http://www.lung.org.

Read more:
Program to focus on lung anatomy and basic medication - Newton Daily News

In search of a good Anthropocene? Physiology can help – OUPblog (blog)

It is generally accepted that the Earth has been irreversibly altered by an ever-growing human population. Indeed, we now refer to our current geologic period as the Anthropocene, to stress the great anthropogenic pressure on the planets atmosphere, geology, and biological diversity. In the face of threats such as habitat loss, pollution, and urban and agricultural expansion, it is easy to feel discouraged about the future prospect of the worlds ecosystems and biodiversity. However, scientists and conservationists have a choice about how to approach their mission to preserve existing habitats and rehabilitate those already in a state of degradation.

While much of the rhetoric surrounding the Anthropocene has been markedly negative, there has recently been a push by many scientists for a more positive narrative. Specifically, researchers are posing the question: can the Anthropocene be good? A good Anthropocene would balance the preservation of the natural world with realistic societal needs and consumption.

Recent research supports the value of a hopeful, rather than doom and gloom, perspective for rallying individuals to action. Messages of optimism are thought to be necessary to broadly engage the public and to attract youth to professional careers in the field of conservation biology. This makes intuitive senseif experts are constantly heard saying that all is lost, it is difficult to expect anyone to be motivated to change their behaviour.

The field of conservation biology is made up of a diversity of scientists and practitioners that use tools such as genetics, physiology, modelling, demographics, psychology, and social science. All of these branches have the capacity to contribute positive and progressive approaches to conservation science. Conservation physiology, one of the more recent, formally conceptualized sub-disciplines, is actively contributing to and proposing avenues for the good Anthropocene movement. Specifically, these pathways focus on taking a proactive approach to conservation, encouraging a pragmatic perspective when approaching conservation dilemmas, establishing an appreciation for environmental resilience, and being active in public outreach and policy-building. Establishing these four avenues as goals will allow conservation professionals to solve conservation problems through evidence-based conservation, better-populated models, an appreciation of the mechanisms underlying population declines, cross-disciplinary collaboration, and a well-informed public.

One example of how this multi-faceted approach can tackle a large-scale conservation problem is well-illustrated by research on clownfish (Amphiprion percula) in the Great Barrier Reef. Firstly, conservation physiology researchers are contributing to proactive conservation by applying knowledge of the respiratory physiology and microbiome of the fish to plan coastal development, determine vulnerability, predict how sediments from dredging may influence populations, and assess the potential for acclimation. The work is also underpinned by pragmatism. There is an appreciation that development is continuing and tactics are needed to diminish the associated impacts as much as possible. By taking an experimental approach aimed at determining threshold levels of suspended sediments that alter fish assemblage patterns, the timing of dredging can be sensitively adjusted to avoid interference with coral and reef fish spawning. As much of the work focuses on establishing thresholds, it also incorporates an appreciation of resilience and aims to determine when the capacity to cope with environmental change may be surpassed. Finally, researchers also made outreach a priority and took advantage of the publics familiarity with clownfish in Disneys Finding Nemo to garner attention about the impacts of habitat alteration on the respiratory health of these native fishes. As a whole, this physiological work has been contributing to evidence-based conservation and restoration plans that help to achieve a better Anthropocene.

Individuals trying to shine a positive light on the Anthropocene believe that leveraging technologies, knowledge, and passionate individuals can accomplish the tasks necessary to maintain nature in perpetuity. As we continue to develop new research foci, attempt to attract new students to our fields, and dedicate ourselves to the preservation of nature, we will do well to remember that conservation is ultimately an act of hope.

Featured image credit:Great Barrier Reef Marine Park. Great barrier reef by Wise Hok Wai Lum. CC BY-SA 4.0 via Wikimedia Commons.

Read more from the original source:
In search of a good Anthropocene? Physiology can help - OUPblog (blog)

New report: Global infectious immunology market forecasts to 2022 – WhaTech

New report onInfectious Immunologymarket is segmented based on types of diseases into HIV, hepatitis, pneumonia, tuberculosis, malaria, inflammatory bowel diseases and autoimmune diseases.

HBV affected nearly1.4 million in the U.S. in 2011. The rising incidence of these infectious diseases creates a worldwide demand for immunological diagnostics and treatment.

The infectious immunology market is segmented based on the types of products used for treatment such as diagnostic kits, instruments and reagents. Diagnostic kits hold the dominant share due to their effectiveness.

Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientifics, Bio-Rad Laboratories and Dr. Reddys Laboratories are the key players in the infectious immunology market.

Get Free Sample Report Of Infectious Immunology Market @bit.ly/2nJW6Ly

Infection involves an attack of disease-causing agents such as bacteria and viruses on the host organisms body that causes disturbances in normal functioning. Immunology is the study of the human bodys resistance to these infections.

The combined study ofinfections and immunologywould help authorities to handle infectious disease conditions including HIV, hepatitis, pneumonia, tuberculosis, malaria, inflammatory bowel diseases and autoimmune diseases. The infectious immunology market comprises of the diagnosis and treatment of these infectious diseases with the help of antigen antibody reactions.

Key benefits

In-depth analysis of various regions would provide a clear understanding of current and future trends so that companies can make region specific plans Comprehensive analysis of the factors that drive and restrict the growth of the infectious immunology market is provided Key regulatory guidelines in various regions which impact the infectious immunology market are critically examined

Enquire Report Of Infectious Immunology Market @bit.ly/2p7Wtk5

...

The rest is here:
New report: Global infectious immunology market forecasts to 2022 - WhaTech

The Q&A: Tyler Curiel – Texas Tribune

With each issue, Trib+Health brings you an interview with experts on issues related to health care. Here is this weeks subject:

Dr. Tyler Curielis a professor in the Department of Medicine and Department of Microbiology, Immunology and Molecular Genetics at the Joe R. & Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio. His areas of research focus on cancer immunotherapy and aging, among other things, and he was recently awarded a grant by the National Institute of Health to continue his cancer research.

Editors note: This interview has been edited for length and clarity.

Trib+Health: Can you expand on your recent findings in cancer immunology?

The Texas Tribune thanks its sponsors. Become one.

Tyler Curiel:After around 40 years of hard work from our group and other groups' parts, were seeing some real successes with immunotherapy for cancer. The big breakthrough came in understanding what the barriers were and overcoming those. One area where we have seen a rapid expansion of knowledge is in immune checkpoint blockade.

When you have a cancer or any type of insult on your body, it turns your immune system off. Cancers have figured out various off switches, and they give a signal to your immune response that the mission has been accomplished. We showed that you can make antibodies to block immune checkpoints your immune system has an off switch out there, and if we can prevent the off switch from doing what it's supposed to do, it can kill the cancer.

For the first time ever, we are starting to see patients with advanced-stage cancers responding to this checkpoint blockade kind of therapy.

Trib+Health:What are some problems you've encountered in the field?

Curiel: Although theres been really good success with this immune checkpoint strategy, the truth is that it only helps a minority of patients. The problem is most people dont respond, and the other thing is we are not good at predicting who will and wont respond.

The question is, how do these immune checkpoints work, and what are they really doing? If they work the way we think they will, then they should be working better, and we should be able to better predict who will and wont respond.

The Texas Tribune thanks its sponsors. Become one.

We have now shown that these immune checkpoint molecules have a lot of extra functions nobody knew about. There are inner signals inside tumor cells that give the cell additional instructions, including things like, "grow faster," "resist therapy," "spread to different parts of the body," and "attract cells to help turn the immune response off," among other things.

Now that we know this, it helps our understanding of who can and can't respond to therapy. We've conducted clinical trials with mice to help overcome new barriers and make this work better.

Trib+Health:What does your work in cancer immunotherapy look like now?

Curiel:We're now talking to biotech and pharma companies to develop new strategies for clinical trials so we can go out there and ask if what we found with mice will work with humans, too. Can we help explain why some people respond really well, but most not at all? We've done all of this in our mice.

Now we have to ask if we can do this in humans, and it looks like we can. That's what another big award from the National Cancer Institute is designed to do, and we are guardedly optimistic this will work.

Trib+Health:What are additional advancements you've made in the aging field, another area of your research?

Curiel:Most people probably don't recognize that the No. 1 risk factor for cancer is age it's not smoking or what you eat. It's no secret the U.S. and world are aging, and there's going to be a big uptick in cancer, just based on that fact.

Many colleagues have shown that immunotherapies that work really well in young people fail in old people. That's not a surprise, but the big surprise is we've been looking at the immune system, and when your immune system ages, the thought was everything works the way it used to work, it just doesn't work as well.

The Texas Tribune thanks its sponsors. Become one.

It turns out, that's not true. Some cells that didn't used to be there when you were young start appearing when you're old, and they do weird things we never knew about. And cells that were there when you were young, instead of doing less of what they used to do, do more of something that's bad for you.

Based on this, we developed the first therapy that's ever been described that will be effective as immunotherapy for cancer in aged mice but not young mice. We are able to understand what happens to the immune system when you age, and we developed therapies that are specific toward aged immune systems so that they will work when you are old and most at risk for cancer.

Trib+Health:Tell me about your presidential award you received in March.

Curiel:The presidential award is to recognize a lot of work from my lab over the last 10 years here at the Health Science Center that helped bring us to this particular point, but also other areas we are working on to improve cancer immunotherapy.

Meet Paige: Our new Facebook Messenger bot helps you keep track of the 85th Legislature. Subscribe by messaging HELLO to m.me/texastribune.org. Learn more.

Read the original post:
The Q&A: Tyler Curiel - Texas Tribune

‘Human behaviour leading cause of accidents’ – The Borneo Post

KUCHING: Human behavior is the leading cause of accidents and fatal accidents in Malaysia according to police statistics.

Director of Bukit Aman Investigation and Traffic Enforcement Department SAC Datuk Mahamad Akhir Darus said analysis showed there were six main offences committed by drivers.

They are speeding, using handphones while driving, cutting queues, driving on emergency lanes, overtaking at double lines and misjudgement while overtaking, Akhir told a press conference after the symbolic handing over of 32 Kawasaki Ninja motorcycles to the Sarawak police contingent here yesterday.

He added that drivers who misjudged the distance while overtaking on dangerous stretches of roads or blindspots were more likely to end up in an accident.

All these (offences) point to the behaviour of drivers. We are not yet disciplined, he said.

On another note, he said ever since the police started to issue summonses to foreign drivers in Malaysia, there was a decrease in the number of offences committed by those drivers.

Among the offences were speeding and illegal parking.

Singaporeans make up the most number of offenders summonsed, followed by the Thais. He, however, was unable to disclose the total number of summonses being issued to the foreigners.

We want to let everyone know that no one is above the law when using the roads in Malaysia. We will also make sure that foreigners pay their summonses before they return to their own country, he added. Operations, he added, were carried out periodically by Bukit Aman with the state contingents that border the neighbouring countries.

Recently, we had an operation at the Kelantan-Thailand border while operations were carried out last year at the Johor Bahru-Singapore and Limbang-Miri-Brunei borders.

The next operation would be carried out at the Sabah-Indonesia border followed by the Sarawak-Indonesia border.

On the installation of the Automated Enforcement System (AES) in Sarawak, Akhir clarified that it came under the jurisdiction of the Road and Transport Department which would decide where the cameras would be installed.

What do you think of this story?

Sad(67%)

Great(33%)

Angry(0%)

Nothing(0%)

Interesting(0%)

Excerpt from:
'Human behaviour leading cause of accidents' - The Borneo Post

Mixed Results with Genetics-Guided Cancer Therapy – MedPage Today

Action Points

Molecular screening of different tumor types led to a matched targeted treatment strategy for a subset of patients with advanced, hard-to-treat cancers, although only a minority of those who were successfully screened and treated derived clinical benefit from the approach, a single-center, single-arm, open-label trial indicated.

Out of a cohort of 1,035 patients, a molecular portrait could be identified in 89% of them, among whom an actionable target was detected in almost half of the group at 49%, reported Fabrice Andre, MD, PhD, of Gustave Roussy Cancer Institute in Villejuif, France, and colleagues. This subsequently led to 199 patients actually receiving a treatment course matched to their specific genomic alternation.

And in this subgroup of patients, clinical benefit as reflected by the percentage of patients who achieved a progression-free survival (PFS) interval on matched therapy (PFS2) that was 1.3-fold longer than the PFS interval achieved on prior therapy (PFS1) was documented in one-third of them, 11% of them being objective responses.

"There are controversies about whether the use of high-throughput genomics could improve outcomes in patients with hard-to-treat cancers," explained Andre and colleagues in Cancer Discovery. "In the present study, we have shown that tumor sequencing improves outcome in 33% of patients with advanced cancers," they added. "Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach."

The Molecular Screening for Cancer Treatment Optimization (MOSCATO) 01 trial involved both adult and pediatric patients with a variety of tumor types. The most common tumors included digestive cancer followed by lung cancer, urological cancers, breast cancer, and head and neck cancer. The median number of prior lines of therapy was 4 and tumor biopsies were successfully taken in the majority of patients.

The approaches used to obtain molecular portraits for the 843 patients in whom such a portrait was identified included targeted sequencing and array comparative genomic hybridization analysis. As investigators noted, both RNA sequencing and whole-exome sequencing were added during the course of the study. "The vast majority of the patients received matched therapy in the context of phase I/II trials," Andre noted. Complete responses were documented in two patients or 1% of those who received matched treatment.

There were also 20 partial responses, 10% of the treated cohort. Disease stabilized in 52% of the group and 17% had progressive disease. "The median follow-up for progression-free survival on matched therapy or PFS2 was 20 months," researchers noted, "and median PFS2 was estimated at 2.3 months." The estimated median overall survival was 11.9 months.

"There are several ways to further improve the efficacy of precision medicine," Andre suggested. First, researchers need better ways with which to identify genomic alterations. For example, although both RNA and whole-exome sequencing were done in a large proportion of patients in the MOSCATO trial, "they were not useful to drive patients to therapy," as he pointed out. Researchers also need to be able to more accurately identify which patients might gain from a genomics approach.

Lastly, scientists need to identify targeted combinations of therapies that might improve clinical outcomes, especially for patients who have more than one driver alteration.

Commenting on the study, Leif Ellisen, MD, PhD, of Massachusetts General Hospital Breast Cancer Center in Boston, felt that overall, the MOSCATO 01 trial was an encouraging study.

"There are a few things that you have to remember about this study in particular and the field in general," Ellisen said. To some degree the "deck was stacked" against the study because patients who previously received standard therapy -- including targeted agents against well-established actionable targets -- were excluded from this trial.

"In other words, the study had already culled out known successes of genotype-driven therapy," Ellisen emphasized.

He also pointed out that the median number of prior therapies was four, so investigators were pitted against advanced disease known to be more aggressive and resistant to treatment. "But the bigger picture is that systematically doing genotypic-directed therapy is really a means to a larger end and that larger end is allowing us to collect the data about the relationship between the genotype of a tumor and response to therapy that informs us how we should treat future patients."

If physicians 30 years ago abandoned chemotherapy for patients with advanced cancer on the grounds that only a minority of them responded to it, "we would never have made any progress in oncology," he added.

"This is really the same story -- because only a minority of patients who benefit from this approach today does not mean that the data we are collecting and correlating with responses is not going to be the thing that allows us to make advances tomorrow as we refine our predictions and more patients can benefit in the future."

The study was supported by Genentech and Sanofi.

Andre disclosed no relevant relationships with industry. One or more coauthors disclosed relationships with Roche/Genentech, AstraZeneca, Lilly, Servier, Merck, Pfizer, Eisai, Actelion, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haliodx, Novartis, Sanofi, Pharmamar, and Pierre Fabre.

Ellisen disclosed no relevant relationships with industry.

2017-04-08T16:00:00-0400

Continue reading here:
Mixed Results with Genetics-Guided Cancer Therapy - MedPage Today

Cancer Genetics to Evaluate Biomarkers for Effector Therapeutics – GenomeWeb

NEW YORK (GenomeWeb) Cancer Genetics said today that it has been hired by Effector Therapeutics to provide clinical biomarker services for Effector's lead product candidate, eFT508 a highly selective oral small molecule inhibitor of MNK1 and MNK2.

Registering provides access to this and other free content.

Already have an account? .

Read the original:
Cancer Genetics to Evaluate Biomarkers for Effector Therapeutics - GenomeWeb

New award for loss of genetic affinity a gain for IVF law – The Straits Times

The Court of Appeal last month created a new compensation award for "loss of genetic affinity" in the case of a baby conceived with the wrong sperm following an IVF mix-up.

Genetic affinity loss refers to the cost and hurt to a parent of being deprived of having a baby with her spouse via reproductive technology through the negligence of a third party.

In the 2010 incident, the woman and her husband went to the Thomson Medical Centre for in-vitro fertilisation (IVF) treatment but a stranger's sperm - instead of her husband's - was used to fertilise her extracted eggs.

The mistake resulted in her giving birth to a baby girl with her genetic make-up but not her husband's. She sued the centre for negligence in 2012 seeking, among other things, damages for the baby's upkeep until she grew up.

The end result: The apex court rejected her upkeep claim but recognised she had suffered loss termed as "genetic affinity". The court said her desire to have a child of her own with her husband "is a basic human impulse, and its loss is keenly and deeply felt".

It pointed out ordinary human parents and children are bound by ties of blood and this fact of biological experience - heredity - carries deep socio-cultural significance. "And when, as in the present case, a person has been denied this experience due to the negligence of others then she has lost something of profound significance and has suffered a serious wrong. This loss of 'affinity' can also result in social stigma and embarrassment arising out of the misperceptions of others, as was the case here."

The five-judge panel placed the compensation sum at 30 per cent of the financial costs of raising Baby P, with the precise sum to be assessed by the High Court. The ground- breaking judgment, unprecedented here or elsewhere, suggests the court is prepared to address compensation for loss in an uncharted area.

Issues of heredity and family become all the more important in an era when IVF is increasingly common and genetic manipulation is well on the way to becoming reality. Gene-editing technology, for example, could in future be used to tweak a child's traits more in favour of one parent than the other.

Problems arise when plans go awry and the court has in a way served notice it will not back away from looking at losses not hitherto compensated within the traditional categories of civil claims. Such issues were highlighted by National University of Singapore (NUS) biomedical ethics researcher G. Owen Schaefer, who underlined the importance of the concept in this "genomic era".

Even family publication parentsworld flagged that after the incident, "it is expected that couples who are seeking alternative methods to conceive would be greatly concerned about this issue".

One practical effect in the immediate case is whether the father could also have been eligible to be compensated for the loss of genetic affinity, just like Baby P's mother. "By recognising loss of genetic affinity as a head, it would appear that the husband as the legal father has also suffered a loss, perhaps even more acutely than the mother as he has no genetic connection with the child," said NUS law faculty professor A. Kumaralingam.

Baby P's father, as her legal parent, has rights and obligations but the rights of her biological father remain to be established or clarified. Lawyers point out that the man has not surfaced to make any civil claim for potential compensa- tion for over six years - the recognised deadline in civil claims - which means that the case is moot.

Medical confidentiality constrains him from being identified to third parties without consent but what of his rights as a biological parent? Parliament passed the Status of Children (Assisted Reproduction Technology) Act in 2013 and it states that interested parties involved in such mix-ups can apply to the court to be declared as parents of the child within two years of the mistake being discovered. The Act does not apply in his case which preceded the Act and one possible unknown is that he could have relinquished his rights formally despite the nexus.

If that were to happen, it would not be without precedent as in the case of the twins at the centre of a custody battle between their Singapore mum and American dad in 2011. It emerged while the twins were here that the biological father was someone else who was understood to have signed his rights away, according to the twins' mother then. Interestingly, the twins knew of this when they were court-ordered to return to the US accompanied by their legal father six years ago. The access tussle between the divorced mum and dad is still ongoing in the US to date.

While the litigation in the case of Baby P is over, it is possible that the biological father may surface at some point in time in the future, for whatever reason, for example, should Baby P gain some prominence that bears notice. Such is the sad saga that while all appears over in the court arena, the affected parties will continue to court the consequences for good.

Such prospects, in this area of law that is in its infancy, bear contemplation, given that the numbers resorting to IVF techniques are expected to rise, and the need to minimise incidents.

In its annual report issued last October, Britain's Human Fertilisation and Embryology Authority (HFEA) said it received reports of 517 incidents, out of approximately 72,000 cycles of fertilisation treatment in 2015. "Whilst incidents make up less than 1 per cent of treatment, any incident is one too many and is one of the reasons we produce this report," added HFEA.

For the year under review, there were no Grade A incidents for the first time in the five years since HFEA was established in Britain. A Grade A category error or incident includes events such as the death of a patient, being implanted with the wrong embryo, or something that affects a large number of patients, such as a storage-unit malfunction.

As IVF continues in an important way to help couples with reproductive difficulties and the numbers multiply, the British examples and the case of Singapore's Baby P illustrate this is a difficult area when incidents arise - as the Court of Appeal suggested in dealing with the case - with ongoing ramifications.

Like others elsewhere, the court here has shied away from the claim for upkeep of the baby on principle, but unlike others, it has inched forward to detect the need for redress by recognising "loss of genetic affinity". What a signal gain for the law's development indeed in finding such an inventive loss.

See the rest here:
New award for loss of genetic affinity a gain for IVF law - The Straits Times

Scientists use time-lapse video to identify cells that trigger blood stem cell development – News-Medical.net

April 10, 2017 at 11:03 PM

Like private investigators on a stake out, St. Jude Children's Research Hospital scientists used patience and video surveillance-like tools to identify cells that trigger blood cell development. The findings offer clues for making blood-forming stem cells in the laboratory that may ultimately help improve access to bone marrow transplantation.

"The research will likely open new avenues of investigation in stem cell biology and blood development and provide insight to aid efforts to make transplantable hematopoietic stem cells in the lab," said corresponding author Wilson Clements, Ph.D., an assistant member of the St. Jude Department of Hematology. The research appears today in the journal Nature Cell Biology.

Blood-forming stem cells are capable of making any type of blood cell in the body. They are also used in transplant therapies for cancers like leukemia or other blood diseases like sickle cell. They are starting to be used to deliver gene therapy. However, a shortage of suitable donors limits access to treatment, and efforts to produce blood from pluripotent stem cells in the laboratory have been unsuccessful. Pluripotent stem cells are the master cells capable of making any cell in the body.

All blood-forming stem cells normally arise before birth from certain endothelial cells found in the interior blood vessel lining of the developing aorta. This process--including how endothelial cells are set on the path to becoming blood stem cells--is not completely understood.

Clements and first author Erich Damm, Ph.D., a St. Jude postdoctoral fellow, have identified trunk neural crest cells as key orchestrators of the conversion of endothelial cells to blood stem cells. Trunk neural crest cells are made in the developing spinal cord and migrate throughout the embryo. They eventually give rise to a variety of adult cells, including neurons and glial cells in the sympathetic and parasympathetic nervous system, which control feeding, fighting, fleeing and procreating.

Using time-lapse video, the researchers tracked the migration of neural crest cells in the transparent embryos of zebrafish. Zebrafish and humans share nearly identical blood systems, as well as the programming that makes them during development. After about 20 hours, the neural crest cells had reached the developing aorta. After hour 24, the migrating cells had cozied up to the endothelial cells in the aorta, which then turned on genes, such as runx1, indicating their conversion to blood stem cells.

The investigators used a variety of methods to show that disrupting the normal migration of neural crest cells or otherwise blocking their contact with the aorta endothelial cells prevented the "birth" of blood stem cells. Meanwhile, other aspects of zebrafish development were unaffected.

"Researchers have speculated that the endothelial cells that give rise to blood-forming stem cells are surrounded by a support 'niche' of other cells whose identity and origins were unknown," Damm said. "Our results support the existence of a niche, and identify trunk neural crest cells as an occupant."

Adult bone marrow includes niches that support normal function and notably feature cells derived from trunk neural crest cells.

The findings also suggest that trunk neural crest cells use a signal or signals to launch blood stem cell production during development. The researchers have eliminated adrenaline and noradrenaline as the signaling molecules, but work continues to identify the signaling proteins or small molecules involved.

Link:
Scientists use time-lapse video to identify cells that trigger blood stem cell development - News-Medical.net

Mighty morphed brain cells cure Parkinson’s in mice, but human trials still far off – STAT

M

ice that walk straight and fluidly dont usually make scientists exult, but these did: The lab rodents all had a mouse version of Parkinsons disease and only weeks before had barely been able to lurch and shuffle around their cages.

Using a trick from stem-cell science, researchers managed to restore the kind of brain cells whose death causes Parkinsons. And the mice walked almost normally.The same technique turned human brain cells, growing in a lab dish, into the dopamine-producing neurons that are AWOL in Parkinsons, scientists at Swedens Karolinska Institute reportedon Monday in Nature Biotechnology.

Success in lab mice and human cells is many difficult steps away from success in patients. The study nevertheless injected new life into a promising approach to Parkinsons that has suffered setback after setback replacing the dopamine neurons that are lost in the disease, crippling movement and eventually impairing mental function.

advertisement

This is not going to happen in five years or possibly even 10, but Im excited about the potential of this kind of cell replacement therapy, said James Beck, chief scientific officer of the Parkinsons Foundation, which was not involved in the study. It could really give life back to someone with Parkinsons disease.

There is no cure for Parkinsons, a neurodegenerative disease that affects an estimated 10 million people worldwide, most prominently actor Michael J. Fox. Drugs that enable the brain to make dopamine help only somewhat, often causing movement abnormalities called dyskinesia as well as bizarre side effects such as a compulsion to gamble; they do nothing to stop the neurodegeneration.

As Parkinsons patients wait, Fox Foundation and scientist feud over drug trial

Rather than replacing the missing dopamine, scientists led by Karolinskas Ernest Arenas tried to replace dopamine neurons but not in the way that researchers have been trying since the late 1980s. In that approach, scientists obtained tissue containing dopamine neurons from first-trimester aborted fetuses and implanted it intopatients brains.Although a 2001clinical trialfound that the transplants partly alleviated the rigidity and tremors of Parkinsons, the procedure caused serious dyskinesia in about 20 percent of patients, Beck said. More problematic is that fetal issue raises ethical concerns and is in short supply.

It was clear that usable fragments of brain tissue were extremely difficult to recover, said Dr. Curt Freed, of the University of Colorado, who pioneered that work.

Instead, several labs have therefore used stem cells to produce dopamine neurons in dishes. Transplanted into the brains of lab rats with Parkinsons, the neurons reduced rigidity, tremor, and other symptoms. Human studies are expected to begin in the US and Japan this year or next, Beck said.

In the Karolinska approach, there is no need to search for donor cells and no cell transplantation or [need for] immunosuppression to prevent rejection, Arenas told STAT. Instead, he and his team exploited one of the most startling recent discoveries in cell biology: that certain molecules can cause one kind of specialized cell, such as a skin cell, to pull a Benjamin Button, aging in reverse until they become like the embryonic cells called stem cells. Those can be induced to morph into any kind of cell heart, skin, muscle, and more in the body.

Muhammad Ali and Parkinsons disease: Was boxing to blame?

Arenas and his team filled harmless lentiviruses with a cocktail of four such molecules. Injected into the brains of mice with Parkinsons-like damage, the viruses infected plentifulbrain cells called astrocytes. (The brains support cells, astrocytes perform jobs like controlling blood flow.)The viruses also infected other kinds of cells, but their payload was designed to work only in astrocytes, and apparently caused no harm to the other cells.

The molecules, called transcription factors, reprogrammed some of the astrocytes to become dopamine neurons, which were first detected three weeks later in the mouse brains. The dopamine neurons were abundant 15 weeks later, an indication that after changing into dopamine neurons the astrocytes stayed changed.

Five weeks after receiving the injections, the mice, which used to have Parkinsons-like gait abnormalities, walked as well as healthy mice. That suggests that direct reprogramming [of brain cells] has the potential to become a novel therapeutic approach for Parkinsons, Arenas told STAT.

That could have value for preserving the brain circuitry destroyed by Parkinsons, said Colorados Freed.

A lot of hurdles need to be overcome before this becomes a Parkinsons treatment. The Trojan horse system for delivering the reprogramming molecules inside viruseswould need to turn more astrocytes into dopamine neurons and leave other kinds of cells alone: Although viruses getting into mouse brain cells apparently caused no harm, that might not be so in people. We will need to use virus with selective [attraction] for astrocytes, Arenas said.

The morphed cells would presumably be ravaged by whatever produced Parkinsons in the first place. But in other cell transplants, Arenas said, the disease catches up with transplanted cells in 15 to 20 years, buying patients a good period of time. He thinks it might be possible to give patients a single injection but hold off some of the reprogramming with a drug, turning it on when the brain again runs short of dopamine neurons.

The basic technology to develop such strategies currently exists, he said.

The Karolinska lab is working to make the techniquesafer and more effective, including by using viruses that would deliver reprogramming molecules only to astrocytes. We are open to collaborations aimed at human studies, Arenas said.

Would patients be willing to undergo brain injections? People with Parkinsons disease, Beck said, are willing to go through a lot for any hope of improvement.

Sharon Begley can be reached at sharon.begley@statnews.com Follow Sharon on Twitter @sxbegle

Excerpt from:
Mighty morphed brain cells cure Parkinson's in mice, but human trials still far off - STAT